Hansa Biopharma AB
(OSTO:HNSA)
kr
42.46
0.62 (1.48%)
Market Cap: 2.78 Bil
Enterprise Value: 3.18 Bil
PE Ratio: 0
PB Ratio: 0
GF Score: 73/100 - Q1 2024 Hansa Biopharma AB Earnings Call TranscriptApr 18, 2024kr29.06 (-1.42%)Earnings
- Q4 2023 Hansa Biopharma AB Earnings Call TranscriptFeb 02, 2024kr31.32 (-7.88%)Earnings
- Hansa Biopharma AB Carlsquare Life Science Investor Day TranscriptDec 06, 2023
- Q3 2023 Hansa Biopharma AB Earnings Call TranscriptOct 26, 2023kr24.42 (-12.28%)Earnings
- Q2 2023 Hansa Biopharma AB Earnings Call TranscriptJul 20, 2023kr45.06 (+1.49%)Earnings
- Q1 2023 Hansa Biopharma AB Earnings Call TranscriptApr 20, 2023kr45.66 (-11.68%)Earnings
- Hansa Biopharma AB at TD Cowen Health Care Conference TranscriptMar 06, 2023
- Q4 2022 Hansa Biopharma AB Earnings Call TranscriptFeb 02, 2023kr53.5 (-12.94%)Earnings
- Nine months 2022 Hansa Biopharma AB Earnings Call TranscriptOct 20, 2022kr53.7 (-8.98%)Earnings
- Q2 2022 Hansa Biopharma AB Earnings Call TranscriptJul 19, 2022kr79 (+40.95%)Earnings
- Q1 2022 Hansa Biopharma AB Earnings Call TranscriptApr 21, 2022kr61.5 (+11.92%)Earnings
- Hansa Biopharma AB Erik Penser Bolagsdag Stockholm TranscriptMar 10, 2022
- Q4 2021 Hansa Biopharma AB Earnings Call TranscriptFeb 03, 2022kr63.8 (-15.09%)Earnings
- Hansa Biopharma AB Deep Dive: Gene Therapy Hosted by HC Andersen Capital TranscriptNov 05, 2021
- Hansa Biopharma AB Redeye Interview TranscriptOct 22, 2021
- Q3 2021 Hansa Biopharma AB Earnings Call TranscriptOct 21, 2021kr109.1 (+0.41%)Earnings
- Hansa Biopharma AB at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 15, 2021
- Q2 2021 Hansa Biopharma AB Earnings Call TranscriptJul 15, 2021kr114.2 (-17.19%)Earnings
- Hansa Biopharma AB Redeye Orphan Drugs Event - Corporate Call TranscriptApr 28, 2021
- Q1 2021 Hansa Biopharma AB Earnings Call TranscriptApr 22, 2021kr179.1 (+12.29%)Earnings
- Full Year 2020 Hansa Biopharma AB Earnings Call TranscriptFeb 04, 2021kr181.5 (+0.55%)Earnings
- Hansa Biopharma AB at JPMorgan Healthcare Conference (Virtual) TranscriptJan 14, 2021
- Hansa Biopharma AB Corporate Analyst Meeting TranscriptOct 29, 2020
- Hansa Biopharma AB at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 18, 2020
- Half Year 2020 Hansa Biopharma AB Earnings Call TranscriptJul 16, 2020kr252 (-2.55%)Earnings
- Hansa Biopharma AB (publ) - Special Call TranscriptJul 02, 2020
- Hansa Biopharma AB at UBS Global Healthcare Conference (Virtual) TranscriptMay 18, 2020
- Q1 2020 Hansa Biopharma AB Earnings Call TranscriptApr 28, 2020kr121.1 (+5.49%)Earnings
- Q4 2019 Hansa Biopharma AB Earnings Call TranscriptFeb 06, 2020kr70.15 (-5.39%)Earnings
- Hansa Biopharma AB (publ) - Special Call TranscriptDec 13, 2019
- Nine Months 2019 Hansa Biopharma AB Earnings Call TranscriptOct 31, 2019kr128.5 (-8.93%)Earnings
- Hansa Biopharma AB at Morgan Stanley Healthcare Conference TranscriptSep 10, 2019
- Q2 2019 Hansa Biopharma AB Earnings Call TranscriptJul 18, 2019kr172.9Earnings
- Hansa Biopharma AB at UBS Global Healthcare Conference TranscriptMay 20, 2019
- Q1 2019 Hansa Biopharma AB Earnings Call TranscriptApr 29, 2019Earnings
Hansa Biopharma AB Redeye Orphan Drugs Event - Corporate Call Transcript
Apr 28, 2021 / NTS GMT
Release Date Price:
kr171.8
(+0.17%)
Niklas Elmhammer
Redeye AB, Research Division - Research Analyst
And next up is Hansa Biopharma, and we will be joined by speaker, Klaus Sindahl, Head of Investor Relations.
Klaus Sindahl;publ;Head of IR
Hansa Biopharma AB
()-
Good morning, and thank you so much for your interest in Hansa Biopharma. Can you hear me?
Niklas Elmhammer
Redeye AB, Research Division - Research Analyst
Yes, absolutely. So please go ahead.
Klaus Sindahl;publ;Head of IR
Hansa Biopharma AB
()-
Okay. Yes. Yes. So my name is Klaus Sindahl, and I'm Head of Investor Relations here at Hansa. And I'm very excited to come here and present Hansa to this orphan drug event. So before I continue, I just need to briefly show you this slide on our forward-looking statements.
So Hansa Biopharma has now progressed into a commercial stage biopharmaceutical company, and we have a broad clinical pipeline in transplantation and in autoimmune
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)